The effect of PLK1 inhibitor in osimertinib resistant non-small cell lung carcinoma cells.
Dai X, Liu X, Ge F, Zhu H, Zheng C, Yan F, Yang B.
Zhejiang Da Xue Xue Bao Yi Xue Ban · research-article; journal article · DOI 10.3724/zdxbyxb-2023-0305 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för GSK461364. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
27 hitsBI6727 and GSK461364A, potent PLK1 inhibitors induce G2/M arrest and apoptosis against cholangiocarcinoma cell lines.
Riantana H, Waenphimai O, Mahalapbutr P, Karnchanapandh K, Vaeteewoottacharn K, Wongkham S, Sawanyawisuth K.
Pathol Res Pract · journal article · DOI 10.1016/j.prp.2023.154678A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis.
Imakura T, Sato S, Koyama K, Ogawa H, Niimura T, Murakami K, Yamashita Y, Haji K, Naito N, Kagawa K, Kawano H, Zamami Y, Ishizawa K, Nishioka Y.
Respir Res · research-article; journal article · DOI 10.1186/s12931-023-02446-xGSK461364A suppresses proliferation of gastric cancer cells and induces apoptosis.
Ataseven D, Taştemur Ş, Yulak F, Karabulut S, Ergul M.
Toxicol In Vitro · journal article · DOI 10.1016/j.tiv.2023.105610Unusually High Affinity of the PLK Inhibitors RO3280 and GSK461364 to HSA and Its Possible Pharmacokinetic Implications.
Fernández-Sainz J, Pacheco-Liñán PJ, Ripoll C, González-Fuentes J, Albaladejo J, Bravo I, Garzón-Ruiz A.
Mol Pharm · research support, non-u.s. gov't; research-article; journal article · DOI 10.1021/acs.molpharmaceut.2c00849Multiomics characterization implicates PTK7 in ovarian cancer EMT and cell plasticity and offers strategies for therapeutic intervention.
Raivola J, Dini A, Karvonen H, Piki E, Salokas K, Niininen W, Kaleva L, Zhang K, Arjama M, Gudoityte G, Seashore-Ludlow B, Varjosalo M, Kallioniemi O, Hautaniemi S, Murumägi A, Ungureanu D.
Cell Death Dis · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41419-022-05161-5Recent Advancements on Benzimidazole: A Versatile Scaffold in Medicinal Chemistry.
Alzhrani ZMM, Alam MM, Nazreen S.
Mini Rev Med Chem · review; journal article · DOI 10.2174/1389557521666210331163810A specific inhibitor of polo-like kinase 1, GSK461364A, suppresses proliferation of Raji Burkitt's lymphoma cells through mediating cell cycle arrest, DNA damage, and apoptosis.
Ergul M, Bakar-Ates F.
Chem Biol Interact · journal article · DOI 10.1016/j.cbi.2020.109288Dual targeting of Polo-like kinase 1 and baculoviral inhibitor of apoptosis repeat-containing 5 in TP53-mutated hepatocellular carcinoma.
Li Y, Zhao ZG, Luo Y, Cui H, Wang HY, Jia YF, Gao YT.
World J Gastroenterol · research-article; journal article · DOI 10.3748/wjg.v26.i32.4786Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer.
Giordano A, Liu Y, Armeson K, Park Y, Ridinger M, Erlander M, Reuben J, Britten C, Kappler C, Yeh E, Ethier S.
PLoS One · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1371/journal.pone.0224420Synergistic Action of Gefitinib and GSK41364A Simultaneously Loaded in Ratiometrically-Engineered Polymeric Nanoparticles for Glioblastoma Multiforme.
Velpurisiva P, Rai P.
J Clin Med · research-article; journal article · DOI 10.3390/jcm8030367GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM).
Velpurisiva P, Piel BP, Lepine J, Rai P.
Bioengineering (Basel) · research-article; journal article · DOI 10.3390/bioengineering5040083PLK1 Inhibition Radiosensitizes Breast Cancer Cells, but Shows Low Efficacy as Monotherapy or in Combination with other Cytotoxic Drugs.
Brassesco MS, Pezuk JA, Salomão KB, Roberto GM, Scrideli CA, Tone LG.
Anticancer Agents Med Chem · research support, non-u.s. gov't; journal article · DOI 10.2174/1871520618666180228155435Polo-like kinase 1 inhibition results in misaligned chromosomes and aberrant spindles in porcine oocytes during the first meiotic division.
Liao Y, Lin D, Cui P, Abbasi B, Chen C, Zhang Z, Zhang Y, Dong Y, Rui R, Ju S.
Reprod Domest Anim · journal article · DOI 10.1111/rda.13102Plk1 is essential for proper chromosome segregation during meiosis I/meiosis II transition in pig oocytes.
Zhang Z, Chen C, Ma L, Yu Q, Li S, Abbasi B, Yang J, Rui R, Ju S.
Reprod Biol Endocrinol · research-article; journal article · DOI 10.1186/s12958-017-0289-7Plk1 inhibition leads to a failure of mitotic division during the first mitotic division in pig embryos.
Zhang Z, Chen C, Cui P, Liao Y, Yao L, Zhang Y, Rui R, Ju S.
J Assist Reprod Genet · research-article; journal article · DOI 10.1007/s10815-016-0864-4The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.
Pajtler KW, Sadowski N, Ackermann S, Althoff K, Schönbeck K, Batzke K, Schäfers S, Odersky A, Heukamp L, Astrahantseff K, Künkele A, Deubzer HE, Schramm A, Sprüssel A, Thor T, Lindner S, Eggert A, Fischer M, Schulte JH.
Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.14268Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel.
Chou YS, Yen CC, Chen WM, Lin YC, Wen YS, Ke WT, Wang JY, Liu CY, Yang MH, Chen TH, Liu CL.
Int J Oncol · research support, non-u.s. gov't; journal article · DOI 10.3892/ijo.2016.3352Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
Shin SB, Woo SU, Yim H.
J Cell Physiol · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1002/jcp.25042BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments.
Bogado RF, Pezuk JA, de Oliveira HF, Tone LG, Brassesco MS.
Anticancer Drugs · research support, non-u.s. gov't; journal article · DOI 10.1097/cad.0000000000000157Overexpression of human ABCB1 in cancer cells leads to reduced activity of GSK461364, a specific inhibitor of polo-like kinase 1.
Wu CP, Hsiao SH, Luo SY, Tuo WC, Su CY, Li YQ, Huang YH, Hsieh CH, Hsieh CH.
Mol Pharm · research support, non-u.s. gov't; journal article · DOI 10.1021/mp500492rCurrent clinical trials with polo-like kinase 1 inhibitors in solid tumors.
Yim H.
Anticancer Drugs · research support, non-u.s. gov't; review; journal article · DOI 10.1097/cad.0000000000000007A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1.
Danovi D, Folarin A, Gogolok S, Ender C, Elbatsh AM, Engström PG, Stricker SH, Gagrica S, Georgian A, Yu D, U KP, Harvey KJ, Ferretti P, Paddison PJ, Preston JE, Abbott NJ, Bertone P, Smith A, Pollard SM.
PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0077053The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.
Russo MA, Kang KS, Di Cristofano A.
Thyroid · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1089/thy.2013.0037Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies.
Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, Barriuso J, Medani H, Degenhardt YY, Allred AJ, Smith DA, Murray SC, Lampkin TA, Dar MM, Wilson R, de Bono JS, Blagden SP.
Clin Cancer Res · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-10-2946Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability.
Degenhardt Y, Greshock J, Laquerre S, Gilmartin AG, Jing J, Richter M, Zhang X, Bleam M, Halsey W, Hughes A, Moy C, Liu-Sullivan N, Powers S, Bachman K, Jackson J, Weber B, Wooster R.
Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-10-0095Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, Hassler DF, Smith GK, Gontarek RR, Courtney MP, Sutton D, Diamond MA, Jackson JR, Laquerre SG.
Cancer Res · journal article · DOI 10.1158/0008-5472.can-09-0945